Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 18, Issue 10, Pages 770-796Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41573-019-0033-4
Keywords
-
Funding
- British Heart Foundation [BHF/TARGETPDE/PG/17/26/32881]
- Medical Research Council [MC-PC-13063, MC-PC-15039]
- [1R01MH101130]
- [1R01AG061200]
- MRC [MR/N003403/1, MC_PC_15039, MC_PC_13063] Funding Source: UKRI
Ask authors/readers for more resources
Phosphodiesterases (PDEs), enzymes that degrade 3',5'-cyclic nucleotides, are being pursued as therapeutic targets for several diseases, including those affecting the nervous system, the cardiovascular system, fertility, immunity, cancer and metabolism. Clinical development programmes have focused exclusively on catalytic inhibition, which continues to be a strong focus of ongoing drug discovery efforts. However, emerging evidence supports novel strategies to therapeutically target PDE function, including enhancing catalytic activity, normalizing altered compartmentalization and modulating post-translational modifications, as well as the potential use of PDEs as disease biomarkers. Importantly, a more refined appreciation of the intramolecular mechanisms regulating PDE function and trafficking is emerging, making these pioneering drug discovery efforts tractable.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available